R SymBio Pharmaceuticals / 4582
CoverageUpdate Notes

Research Coverage Report by Shared Research Inc. | www.sharedresearch.jp

This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this latest update, isavailable on our website at http://www.sharedresearch.jp and various professional platforms. Our sponsored research reports provide an in-depth
and informative view of the companies we cover, and contain the latest available information updated in a timely manner.

On September 21, 2017, SymBio Pharmaceuticals Ltd. announced revisions to its full-year FY12/17 earnings forecasts.

Revised FY12/17 company earnings forecasts▷Sales: JPY3.6bn (previous forecast: JPY2.9bn)▷Recurring loss:

JPY4.0bn (JPY3.3bn)

Net loss:

JPY4.0bn (JPY3.3bn)▷▷

Operating loss: JPY3.9bn (JPY3.2bn)

Reasons for revisions
The company expects sales of JPY3.6bn, exceeding its previous forecast by JPY680mn, because sales of Treakisym® in Japan grewfaster than expected following approval for the new indication of first-line treatment of low-grade non-Hodgkin’s lymphoma(NHL) and mantle cell lymphoma (MCL) in December 2016. The company expects operating profit, recurring profit, and net
profit to be lower than its previous forecast due to the upfront payment relating to the license agreement with Eagle
Pharmaceuticals, Inc., for the liquid formulation products of bendamustine hydrochloride, although SG&A expenses have beensolidly controlled within budget.

This note is the most recent addition to the full report.

1/2

R About Shared Research Inc.
Coverage

Research Coverage Report by Shared Research Inc. | www.sharedresearch.jp

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously
updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at http://www.sharedresearch.jp.

Disclaimer
This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty,
either expressed or implied, regarding the veracity of data or interpretations of data included in this report. We shall not be held responsible for any damage caused by
the use of this report.
The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared
Research. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of thecopyright of this report. Our officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may
affect this report’s objectivity.

Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer
The report has been prepared by Shared Research under a contract with the company described in this report (“the company”). Opinions and views presented are ours
where so stated. Such opinions and views attributed to the company are interpretations made by Shared Research. We represent that if this report is deemed to include
an opinion by us that could influence investment decisions in the company, such opinion may be in exchange for consideration or promise of consideration from thecompany to Shared Research.

Contact Details
Shared Research Inc.
3-31-12 Sendagi Bunkyo-ku Tokyo, Japan
http://www.sharedresearch.jp
Phone: +81 (0)3 5834-8787
Email: info@sharedresearch.jp

2/2